



Marine Genetic Resources (MGRs)




Widely used in pharmaceuticals: deep-sea sponges

- What: any material of marine plant, animal, microbial or other origin containing functional units of heredity
- Why: Used in pharmaceuticals, cosmetics, biotechnology, etc. -> (Could) have (significant) economic value
- With what goal: Fair and equitable sharing of benefits arising from activities with respect to marine genetic resources and **digital sequence information** (Art. 7)
- **How?** -> next slides
- **Main take-aways: flexible mechanism, all benefits flow to the implementation of BBNJ: conservation, sustainable use & capacity-building**


How I: key provisions



How II: governance mechanism



Assessment

Solutions	Challenges
<ul style="list-style-type: none"> + guaranteeing benefit-sharing consisting of access, participation & monetary benefits related to commercialization (G77 demanded no hand-out but right to commercially oriented fee) 	<ul style="list-style-type: none"> - some notification/reporting burden for researchers & companies (EU + likeminded wanted to avoid burdensome track & trace)
 <p>Balance</p>	
<ul style="list-style-type: none"> + all monetary benefits for the implementation of BBNJ: conservation, sustainable use & capacity-building 	<ul style="list-style-type: none"> - can it include private multi-national companies? - Many “where practicable” - Incentives
<ul style="list-style-type: none"> + flexible: future system & inclusion of DSI can be harmonized with global benefit-sharing system under CBD 	<ul style="list-style-type: none"> - still, DSI issue likely to politicize COP decisions

Questions?

*Arne Langlet
ERC Project MARIPOLDATA
University of Vienna
arne.langlet@univie.ac.at*